Paul M. Ridker

1.4k total papers · 232.0k total citations
817 papers, 131.2k citations indexed

About

Paul M. Ridker is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Paul M. Ridker has authored 817 papers receiving a total of 131.2k indexed citations (citations by other indexed papers that have themselves been cited), including 341 papers in Surgery, 249 papers in Cardiology and Cardiovascular Medicine and 244 papers in Epidemiology. Recurrent topics in Paul M. Ridker's work include Lipoproteins and Cardiovascular Health (287 papers), Adipokines, Inflammation, and Metabolic Diseases (214 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (133 papers). Paul M. Ridker is often cited by papers focused on Lipoproteins and Cardiovascular Health (287 papers), Adipokines, Inflammation, and Metabolic Diseases (214 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (133 papers). Paul M. Ridker collaborates with scholars based in United States, Netherlands and United Kingdom. Paul M. Ridker's co-authors include Nader Rifai, Peter Libby, Julie E. Buring, Nancy R. Cook, Charles H. Hennekens, Robert J. Glynn, Meir J. Stampfer, Attilio Maseri, JoAnn E. Manson and Samia Mora and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Paul M. Ridker

809 papers receiving 126.4k citations

Hit Papers

Inflammation and Atherosc... 1995 2026 2005 2015 2002 2008 1997 2009 2011 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Inflammation and Atherosclerosis
    2002 6.0k citations Peter Libby, Paul M. Ridker et al. Circulation profile →
  2. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
    2008 4.7k citations Paul M. Ridker, Eleanor Danielson et al. New England Journal of Medicine profile →
  3. Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
    1997 4.4k citations Paul M. Ridker, Mary Cushman et al. New England Journal of Medicine profile →
  4. Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
    2009 3.0k citations Paul M. Ridker, Eleanor Danielson et al. Obstetrical & Gynecological Survey profile →
  5. Progress and challenges in translating the biology of atherosclerosis
    2011 2.9k citations Peter Libby, Paul M. Ridker et al. Nature profile →
  6. Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
    2002 2.7k citations Paul M. Ridker, Nader Rifai et al. New England Journal of Medicine profile →
  7. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention
    2003 2.0k citations Paul M. Ridker Circulation profile →
  8. Plasma Concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men
    2000 1.9k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  9. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events
    2003 1.8k citations Paul M. Ridker, Julie E. Buring et al. Circulation profile →
  10. Lack of Effect of Long-Term Supplementation with Beta Carotene on the Incidence of Malignant Neoplasms and Cardiovascular Disease
    1996 1.7k citations Charles H. Hennekens, Julie E. Buring et al. New England Journal of Medicine profile →
  11. C-Reactive Protein Levels and Outcomes after Statin Therapy
    2005 1.7k citations Paul M. Ridker, Christopher P. Cannon et al. New England Journal of Medicine profile →
  12. Inflammation in Atherosclerosis
    2009 1.6k citations Peter Libby, Paul M. Ridker et al. Journal of the American College of Cardiology profile →
  13. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
    2005 1.4k citations Paul M. Ridker, Nancy R. Cook et al. New England Journal of Medicine profile →
  14. Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy Women
    1998 1.3k citations Paul M. Ridker, Julie E. Buring et al. Circulation profile →
  15. Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women
    2007 1.3k citations Paul M. Ridker, Julie E. Buring et al. JAMA profile →
  16. Effect of Statin Therapy on C-Reactive Protein Levels
    2001 1.3k citations Michelle A. Albert, Nader Rifai et al. JAMA profile →
  17. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events
    2001 1.2k citations Paul M. Ridker, Nader Rifai et al. New England Journal of Medicine profile →
  18. Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women
    2007 1.2k citations Sandeep Bansal, Julie E. Buring et al. JAMA profile →
  19. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
    1999 1.2k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  20. High-Sensitivity C-Reactive Protein
    2001 1.1k citations Paul M. Ridker Circulation profile →
  21. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
    1998 1.1k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  22. Inflammation as a Cardiovascular Risk Factor
    2004 1.0k citations James T. Willerson, Paul M. Ridker Circulation profile →
  23. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
    1998 1.0k citations Paul M. Ridker, Charles H. Hennekens et al. The Lancet profile →
  24. Effect of sleep loss on C-Reactive protein, an inflammatory marker of cardiovascular risk
    2004 914 citations Paul M. Ridker, Nader Rifai et al. Journal of the American College of Cardiology profile →
  25. Blood Levels of Long-Chain n–3 Fatty Acids and the Risk of Sudden Death
    2002 885 citations Christine M. Albert, Hannia Campos et al. New England Journal of Medicine profile →
  26. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
    2016 848 citations Amit V. Khera, Connor A. Emdin et al. New England Journal of Medicine profile →
  27. Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer
    2005 841 citations I‐Min Lee, Nancy R. Cook et al. JAMA profile →
  28. Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
    1995 831 citations Paul M. Ridker, Charles H. Hennekens et al. New England Journal of Medicine profile →
  29. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies
    2011 828 citations David Wormser, Stephen Kaptoge et al. The Lancet profile →
  30. C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction
    1998 804 citations Paul M. Ridker, Robert J. Glynn et al. Circulation profile →
  31. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction
    2000 776 citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  32. Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease
    1998 773 citations Paul M. Ridker, Mary Cushman et al. Circulation profile →
  33. Efficient Bayesian mixed-model analysis increases association power in large cohorts
    2015 759 citations Po‐Ru Loh, George Tucker et al. Nature Genetics profile →
  34. Physical Activity and Reduced Risk of Cardiovascular Events
    2007 748 citations Samia Mora, Nancy R. Cook et al. Circulation profile →
  35. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
    2009 747 citations Paul M. Ridker, Eleanor Danielson et al. The Lancet profile →
  36. Prevention Conference V
    2000 743 citations Philip Greenland, Michael H. Criqui et al. Circulation profile →
  37. Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
    2005 728 citations Mukesh K. Jain, Paul M. Ridker Nature Reviews Drug Discovery profile →
  38. From C-Reactive Protein to Interleukin-6 to Interleukin-1
    2016 680 citations Paul M. Ridker Circulation Research profile →
  39. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    2001 639 citations Paul M. Ridker, Nader Rifai et al. profile →
  40. C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction
    2008 626 citations Paul M. Ridker, Nina P. Paynter et al. Circulation profile →
  41. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
    2011 606 citations Paul M. Ridker, Tom Thurén et al. American Heart Journal profile →
  42. Low-Dose Aspirin in the Primary Prevention of Cancer
    2005 602 citations Nancy R. Cook, I‐Min Lee et al. JAMA profile →
  43. Novel Clinical Markers of Vascular Wall Inflammation
    2001 592 citations Gavin J. Blake, Paul M. Ridker Circulation Research profile →
  44. Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
    2005 583 citations Paul M. Ridker, Nader Rifai et al. JAMA profile →
  45. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
    2012 572 citations S. Matthijs Boekholdt, Benoît J. Arsenault et al. JAMA profile →
  46. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    2012 560 citations Paul M. Ridker, Aruna D. Pradhan et al. The Lancet profile →
  47. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
    2009 558 citations Jasper J. Brugts, Tuncay Yetgin et al. BMJ profile →
  48. Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
    2003 553 citations Paul M. Ridker, Samuel Z. Goldhaber et al. New England Journal of Medicine profile →
  49. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay
    1999 549 citations Nader Rifai, Russell P. Tracy et al. Clinical Chemistry profile →
  50. Blood Pressure and Inflammation in Apparently Healthy Men
    2001 547 citations Richard Lee, Nader Rifai et al. Hypertension profile →
  51. Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease
    2002 542 citations Aruna D. Pradhan, JoAnn E. Manson et al. JAMA profile →
  52. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
    2009 542 citations Robert J. Glynn, Eleanor Danielson et al. New England Journal of Medicine profile →
  53. Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?
    2004 500 citations Paul M. Ridker, Peter W.F. Wilson et al. Circulation profile →
  54. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
    2019 452 citations Brendan M. Everett, Jan H. Cornel et al. Circulation profile →
  55. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
    2015 451 citations Jessica L. Mega, Nathan O. Stitziel et al. The Lancet profile →
  56. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
    2021 411 citations Paul M. Ridker, Matt Devalaraja et al. The Lancet profile →
  57. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
    2021 391 citations Paul M. Ridker, Manas Rane Circulation Research profile →
  58. Inflammation, Immunity, and Infection in Atherothrombosis
    2018 391 citations Peter Libby, Joseph Loscalzo et al. Journal of the American College of Cardiology profile →
  59. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
    2018 389 citations Paul M. Ridker, Peter Libby et al. European Heart Journal profile →
  60. Sugar-Sweetened Beverages and Genetic Risk of Obesity
    2012 380 citations Qibin Qi, Audrey Y. Chu et al. New England Journal of Medicine profile →
  61. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
    2018 355 citations Peter Willeit, Paul M. Ridker et al. The Lancet profile →
  62. Statins: new American guidelines for prevention of cardiovascular disease
    2013 322 citations Paul M. Ridker, Nancy R. Cook The Lancet profile →
  63. A Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians
    2015 319 citations Heejung Shim, Daniel I. Chasman et al. PLoS ONE profile →
  64. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
    2013 314 citations Amit Khera, Brendan M. Everett et al. Circulation profile →
  65. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
    2023 301 citations Paul M. Ridker, Deepak L. Bhatt et al. The Lancet profile →
  66. A Test in Context
    2016 270 citations Paul M. Ridker Journal of the American College of Cardiology profile →
  67. Targeting cardiovascular inflammation: next steps in clinical translation
    2020 262 citations Patrick R. Lawler, Deepak L. Bhatt et al. European Heart Journal profile →
  68. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab
    2022 206 citations E. C. Svensson, Aviv Madar et al. JAMA Cardiology profile →
  69. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
    2022 133 citations Thimoteus Speer, Stefanie Dimmeler et al. Nature Reviews Nephrology profile →
  70. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
    2023 96 citations Valentı́n Fuster, Paul M. Ridker et al. Journal of the American College of Cardiology profile →
  71. Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
    2024 90 citations Paul M. Ridker, M. Vinayaga Moorthy et al. New England Journal of Medicine profile →
  72. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study
    2025 15 citations G. Kees Hovingh, S. Matthijs Boekholdt et al. European Heart Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Paul M. Ridker 41.7k 38.6k 32.3k 24.1k 21.0k 817 131.2k
Peter Libby 39.3k 0.9× 35.6k 0.9× 25.3k 0.8× 11.8k 0.5× 48.8k 2.3× 767 147.4k
Nader Rifai 20.9k 0.5× 21.4k 0.6× 21.5k 0.7× 16.4k 0.7× 9.1k 0.4× 454 76.9k
Scott M. Grundy 51.2k 1.2× 39.8k 1.0× 31.8k 1.0× 60.3k 2.5× 5.2k 0.2× 604 160.1k
Peter W.F. Wilson 31.0k 0.7× 35.1k 0.9× 14.4k 0.4× 29.8k 1.2× 3.7k 0.2× 645 110.2k
Daniel Levy 25.2k 0.6× 90.6k 2.3× 13.8k 0.4× 19.4k 0.8× 4.4k 0.2× 816 142.7k
Yūji Matsuzawa 14.8k 0.4× 16.6k 0.4× 36.7k 1.1× 13.5k 0.6× 8.3k 0.4× 700 80.3k
Russell P. Tracy 13.3k 0.3× 23.2k 0.6× 19.5k 0.6× 11.6k 0.5× 7.6k 0.4× 672 87.4k
Børge G. Nordestgaard 27.0k 0.6× 16.9k 0.4× 10.5k 0.3× 18.9k 0.8× 5.3k 0.3× 952 65.5k
Christie M. Ballantyne 29.1k 0.7× 19.7k 0.5× 9.0k 0.3× 16.9k 0.7× 8.7k 0.4× 1.1k 66.1k
Meir J. Stampfer 15.3k 0.4× 17.3k 0.4× 15.5k 0.5× 26.1k 1.1× 4.9k 0.2× 852 142.0k

Countries citing papers authored by Paul M. Ridker

Since Specialization
Citations

This map shows the geographic impact of Paul M. Ridker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul M. Ridker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul M. Ridker more than expected).

Fields of papers citing papers by Paul M. Ridker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul M. Ridker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul M. Ridker. The network helps show where Paul M. Ridker may publish in the future.

Co-authorship network of co-authors of Paul M. Ridker

This figure shows the co-authorship network connecting the top 25 collaborators of Paul M. Ridker. A scholar is included among the top collaborators of Paul M. Ridker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul M. Ridker. Paul M. Ridker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susan Michie Breakdown of academic impact, for papers by G. Jeffrey Snyder Breakdown of academic impact, for papers by Michael I. Jordan Breakdown of academic impact, for papers by Marc G. Caron Breakdown of academic impact, for papers by Mihai G. Netea Breakdown of academic impact, for papers by Michael Tomasello Breakdown of academic impact, for papers by Chris Frith Breakdown of academic impact, for papers by Yoshio Bando
Rankless by CCL
2026